The University of Hyderabad continues to be a fertile ground for high-impact innovation, as evidenced by the remarkable trajectory of SCIINV Biosciences Pvt Ltd. Incubated within ASPIRE BioNEST, the university’s premier life-sciences incubation centre, this female-led biotech startup is tackling one of the 21st century’s greatest global health threats: Antimicrobial Resistance (AMR).
Founded in August 2022 by Dr. Uma Rani, PV Lakshmi, and P. Anasuya, SCIINV Biosciences has rapidly transitioned from a university-based startup to an internationally recognized player in AI-driven diagnostics and novel therapeutics.
MoU exchange between Microbira and SCIINV Biosciences. L to R. Dr.Anil CEO ASPIRE BioNEST, Prof Reddanna Pallu, Sr.Prof (Retd) SLS UOH, Marianne Ismail, CEO Microbira UK, Krishna Burri, COO SCIINV Biosciences, Dr.Ratnakar Palakodeti, Co-founder SCIINV Biosciences.
A Milestone-Driven Journey
In just a few years, SCIINV has secured a valuation of $3 million and established a robust intellectual property portfolio. Their flagship innovation, AMRx®, an AI-first digital diagnostic tool, has garnered significant global attention:
- Global Recognition: Featured in the Microsoft Top 200 AI First Movers coffee table book.
- Award-Winning Solutions: Recipient of the BW Businessworld Healthcare Excellence Award 2025 and the Economic Times Best Healthcare Solution of the Year.
- International Protection: AMRx® is now a registered international trademark under the WIPO Madrid Protocol.
Economic Times Best Healthcare Solution of the Year award. L to R. Ravi Meduri, CTO Innominds Inc, Dr,Ratnakar Palakodeti Co-Founder, SCIINV Biosciences, Dr.Pradeep BE, Academic Advisor SCIINV Biosciences, Krishna Burri COO SCIINV Biosciences. Award is presented in New Delhi by Dr. S.K.Gupta Director AIIMS Jammu.
Innovation Pipeline & Strategic Partnerships
SCIINV’s dual-pronged business model focuses on both immediate diagnostic precision and long-term therapeutic solutions:
- Digital Diagnostics (SaaS): The AMRx® platform provides early and accurate pathogen detection, reducing the dangerous misuse of broad-spectrum antibiotics.
- Novel Therapeutics: The company has successfully completed preclinical studies for novel antimicrobials, with three patents currently submitted and one filed under the 505(b)(2) regulatory pathway.
- Global Collaboration: In June 2025, the company announced a strategic partnership with UK-based Microbira Ltd. This collaboration integrates SCIINV’s AMRx with Microbira’s MAAP IR to create next-generation diagnostic platforms for the global market.
Nurturing the Ecosystem
As a proud product of the UoH ecosystem, SCIINV Biosciences exemplifies the successful translation of university research into real-world applications. While the startup has thrived within the university’s supportive environment—training interns and generating an expected revenue of $500K by March 2026—the founders suggest that the establishment of a GMP (Good Manufacturing Practice) facility would further accelerate the scale-up of biotech ventures on campus.
– By Ms. Aswathy P B, MA Communication (Media Practice)